The uniqueness of this study lies in the fact that the cells used for the transplant were derived from the patient’s own body, reducing the risk of rejection typically associated with donor samples. By injecting the stem cells into the abdominal muscles instead of the liver, researchers were able to closely monitor the cells and adjust the treatment as needed. This personalized approach resulted in the woman producing sufficient insulin to no longer require additional doses by the two-and-a-half-month mark.
Does This Represent a Cure for Type 1 Diabetes?
While this case signifies a remarkable advancement in diabetes treatment, it is crucial to replicate the results in multiple individuals to confirm its effectiveness. Long-term monitoring is necessary to assess the sustained impact of the transplant beyond the one-year mark. The woman in the study was also taking immune-suppressing drugs due to a previous liver transplant, raising questions about the potential influence on her body’s acceptance of the stem cells. Further research is needed to determine the widespread applicability and success of this treatment, emphasizing the importance of continued advocacy for accessible insulin options for all individuals managing diabetes.
Well+Good articles reference scientific, reliable, recent, robust studies to back up the information we share. You can trust us along your wellness journey.
- Wang, Shusen, et al. “Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.” Cell, Sept. 2024, https://doi.org/10.1016/j.cell.2024.09.004
- Wu, J., Li, T., Guo, M. et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov 10, 45 (2024). https://doi.org/10.1038/s41421-024-00662-3
